Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?
Przemysław Seweryn, Andrzej Emeryk, Maciej Kupczyk, Radosław Gawlik, Tomasz Dębowski, Grzegorz Sztaba, Rafał Pawliczak
{"title":"Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?","authors":"Przemysław Seweryn, Andrzej Emeryk, Maciej Kupczyk, Radosław Gawlik, Tomasz Dębowski, Grzegorz Sztaba, Rafał Pawliczak","doi":"10.5114/pja.2023.131710","DOIUrl":null,"url":null,"abstract":"AMA Seweryn P, Emeryk A, Kupczyk M, et al. Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology. 2023;10(3):189-201. doi:10.5114/pja.2023.131710. APA Seweryn, P., Emeryk, A., Kupczyk, M., Gawlik, R., Dębowski, T., & Sztaba, G. et al. (2023). Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology, 10(3), 189-201. https://doi.org/10.5114/pja.2023.131710 Chicago Seweryn, Przemysław, Andrzej Emeryk, Maciej Kupczyk, Radosław Gawlik, Tomasz Dębowski, Grzegorz Sztaba, and Rafał Pawliczak. 2023. \"Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?\". Alergologia Polska - Polish Journal of Allergology 10 (3): 189-201. doi:10.5114/pja.2023.131710. Harvard Seweryn, P., Emeryk, A., Kupczyk, M., Gawlik, R., Dębowski, T., Sztaba, G., and Pawliczak, R. (2023). Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology, 10(3), pp.189-201. https://doi.org/10.5114/pja.2023.131710 MLA Seweryn, Przemysław et al. \"Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?.\" Alergologia Polska - Polish Journal of Allergology, vol. 10, no. 3, 2023, pp. 189-201. doi:10.5114/pja.2023.131710. Vancouver Seweryn P, Emeryk A, Kupczyk M, Gawlik R, Dębowski T, Sztaba G et al. Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology. 2023;10(3):189-201. doi:10.5114/pja.2023.131710.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"42 1","pages":"0"},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2023.131710","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
AMA Seweryn P, Emeryk A, Kupczyk M, et al. Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology. 2023;10(3):189-201. doi:10.5114/pja.2023.131710. APA Seweryn, P., Emeryk, A., Kupczyk, M., Gawlik, R., Dębowski, T., & Sztaba, G. et al. (2023). Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology, 10(3), 189-201. https://doi.org/10.5114/pja.2023.131710 Chicago Seweryn, Przemysław, Andrzej Emeryk, Maciej Kupczyk, Radosław Gawlik, Tomasz Dębowski, Grzegorz Sztaba, and Rafał Pawliczak. 2023. "Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?". Alergologia Polska - Polish Journal of Allergology 10 (3): 189-201. doi:10.5114/pja.2023.131710. Harvard Seweryn, P., Emeryk, A., Kupczyk, M., Gawlik, R., Dębowski, T., Sztaba, G., and Pawliczak, R. (2023). Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology, 10(3), pp.189-201. https://doi.org/10.5114/pja.2023.131710 MLA Seweryn, Przemysław et al. "Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?." Alergologia Polska - Polish Journal of Allergology, vol. 10, no. 3, 2023, pp. 189-201. doi:10.5114/pja.2023.131710. Vancouver Seweryn P, Emeryk A, Kupczyk M, Gawlik R, Dębowski T, Sztaba G et al. Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology. 2023;10(3):189-201. doi:10.5114/pja.2023.131710.
期刊介绍:
Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.